MK-677 SARM / SECRETOGOGUE Information

Pushtoday

MuscleChemistry Registered Member
The catalog chemical chain MK-677 is a catalog chemical that occasionally goes by the name of Ibutamoren or L-163,191. It is a secretogogue, meaning that it is a substance that triggers the secretion of a secondary substance. Its molecular formula is C27H36N4O5S, and it has a molecular mass of 528.662.


MK-677 AT A GLANCE


According to scientific studies based on animal test subjects, the chief function behind MK-677 is to boost the production increase of the following substances:


Ghrelin
IGF-1
Ghrelin is a self-regulated 28 amino acid chain that is primarily produced by the stomach, although it can also be secreted by the epsilon cells that are found within the pancreas. The main function behind the secretion of ghrelin is to stimulate the sensation of being hungry. The enzyme serves as a counter to the enzyme secretion leptin, which is produced to stimulate the sensation of being full. The increase in the production of ghrelin can cause an animal test subject to want to consume more food, and it can allow this desire to eat to come through a more efficient means. It can also mean that the animal test subject will experience a greater capacity to intake a greater amount of food in one setting.


IGF-1, on the other hand, is a secretion that is short for Insulin Growth Factor-1. It is a protein that is secreted by the liver of animal test subjects. The relationship between ghrelin and IGF-1 is symbiotic. As the animal test subject is given an increased capacity to consume more food for fuel because of the secretion of ghrelin, the secretion of IGF-1 allows the increased fuel that is converted to be distributed to muscular and skeletal cells on a more efficient basis. Ultimately, this boost in protein synthesis that is caused by the increase of both ghrelin and IGF-1 as brought about by MK-677 allows the animal test subject to achieve a level of homeostasis on a substantially more efficient basis in terms of protein synthesis.


THEORETICAL BENEFITS BEHIND MK-677


Because of the way in which MK-677 works in conjunction with both ghrelin and IGF-1, scientific study based on animal test subjects has determined that the presence of the catalog chemical could play a vital role in treating various conditions that are related to a disruption of protein synthesis homeostasis.


One of the chief treatments that have been studied relates to the concept of frailty amongst the elderly. Because of the way in which MK-677 works to boost the production of IGF-1 – and how it can use a boost of ghrelin to cajole animal test subjects into consuming for food for fuel – it is thought that this more efficient means of producing muscular and skeletal tissue could allow the bones and muscles of elderly subjects to remain consistently strong. It is also thought that it could counteract issues that are related to the degenerative loss of skeletal and muscle mass, such as sarcopenia.


Other scientific study based on animal test subjects has been able to hypothetically link the presence of MK-677 with a more efficient means of weight regulation. Despite the fact that the presence of the catalog chemical encourages a greater consumption of more food, it has been shown that the protein synthesis that is linked to the increase in IGF-1 production causes the conversion of food into energy to happen on a more efficient basis. Furthermore, this boosted process also allows the breaking down of adipose tissue – that is, body fat – to be broken down on a much more efficient basis. Therefore, it is thought that the presence of MK-677 could make it easier for an animal test subject to retain a more efficient means of weight-related homeostasis.

MK-677 AND FRAILTY


Because of the way in which MK-677 has been shown to boost bone density in animal test subjects, there has been scientific study devoted to determining the catalog chemical’s role in hypothetically batting conditions pertaining to the condition of frailty. Specifically, study has been devoted to determining its usefulness in slowing the condition known as sarcopenia.


In essence, sarcopenia is defined as the degenerative loss of skeletal muscle mass, quality, and strength that is linked to the process of aging. It is not considered a disease or a syndrome unto itself, but rather as a component of the frailty syndrome. Furthermore, sarcopenia can be split off from other body weakening issues like cachexia (that is, wasting syndrome) because those particular conditions are typically listed as secondary by-products of a more prominent underlying pathos, like cancer. It is thought that because of the way in which MK-677 can bring about a more efficient means of producing secretions – which could in turn promote a more efficient means of building up muscular and skeletal tissue – this action could counterbalance the effects of sarcopenia, thus allowing animal test subjects the ability to achieve skeletal muscle-based homeostasis for a longer period of time.


MK-677 AND OTHER SECRETOGOGUES


Scientific study that has been based on animal test subjects has determined that MK-677 has slightly different properties than other secretogogues such as GHRP-6. This determination was not always the case, as it was previously thought that it was indistinguishable in vitro and in vivo from a functionality standpoint. Yet it was determined after oral administration in animal test subjects, which activates the catalog chemical, it was significantly more efficacious than other secretogogues, putting forth a mean peak GH concentration of 22.1 μg/L based on an oral dosage of 25 mg.


MK-677 AND CATABOLISM


Further scientific study that has been based on animal test subjects has been done to determine MK-677’s linke to catabolism. That is, the group of metabolic pathways that breaks down molecules into smaller units as a means to release energy. Studies have indicated that typical dietary energy restrictions bring about an expected catabolic response in normal animal test subjects. The fact there is a loss of nitrogen involved in this process points to an association with a decrease in IGF-1 and a boost in other secretions that are related to growth. This has led to the notion that there may be growth secretion-related resistance, although it is not absolute because of the introduction to a secretogogue will cause a boost in IGF-1 and an uptick in nitrogen retention. Because MK-677’s ability to induce a higher rate of production in secretions such as IGF-1, it has been hypothesized that the presence of the catalog chemical could reverse the typical catabolic response that healthy animal test subjects would have in dietary energy restrictions.


By extension, these studies have suggested that the presence of the catalog chemical could also be an effective aid in treating various acute or chronic disease states that are linked to catabolism. Some of these conditions have been linked to deficiencies in terms of an animal test subject’s normal rate of growth and development.


SIDE EFFECTS OF MK-677


It has been determined that the most prominent side effect of MK-677 is an increase in appetite. This is to be expected, since the catalog chemical’s presence promotes an increase in the production of ghrelin, which in turn causes the feeling of hunger on a significantly more efficient basis. Yet in some respects, this may be difficult to view as an actual side effect. The intake of more food provides the fuel needed for the increase in IGF-1 that is created, which is also a by-product of MK-677’s presence. Yet theoretically, it could be feasible for an animal test subject to increase its food intake at a rate that is higher than the rate of IGF-1 that is being produced, which could in turn cause an increase in weight.


MK-677 AND SLEEP PATTERNS


It has also been determined through scientific study on animal test subjects that MK-677 could conceivably induce a more efficient means of inducing deep sleep. The rationale behind this is linked to the catalog chemical’s ability to increase the production of ghrelin and IGF-1. Because the production of these two secretions occur during a time in which the animal test subject achieves deep sleep, it is thought that a longer period of deep sleep is induced in order to provide a sufficient interval of time for the boost in secretions – and their ultimate functions – to occur.
 
Back
Top